A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

This study is testing whether giving two broadly neutralizing antibodies (bNAbs — laboratory-made proteins that can block HIV) along with standard HIV treatment (ART) can help people who were treated very early after HIV infection achieve long-term HIV control, potentially reducing reliance on daily pills. **You may be eligible if...** - You are between 18 and 60 years old - You started HIV treatment (ART) within 6 months of your estimated time of infection - You can provide evidence of recent HIV infection (such as a recent negative test followed by a positive test) - You are willing to attend regular follow-up visits and provide blood samples **You may NOT be eligible if...** - You started HIV treatment more than 6 months after estimated infection - You have a documented resistance to the antibodies being tested - You have significant other health conditions that would make participation unsafe - You are pregnant or planning to become pregnant during the study Talk to your doctor to see if this trial is right for you.